'Grail' Develops Pan-Cancer Screening Test Designed to Detect Cancers at an Early Stage

California Based Startup ‘Grail’ Develops Pan-Cancer Screening Test Designed to Detect Cancers at an Early Stage

| < 1 minute read

Headquartered in: Menlo Park, California, United States

Founders: Alex Aravanis, Jeff Huber, Mostafa Ronaghi

Founded date: 2016

Hub tags: Exited Unicorn


Grail pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection.

Grail plans to launch Galleri, a lab-developed test to detect cancers early in the blood, commercially next year. The company says the test has greater than 99% specificity and 93% tissue-of-origin accuracy to detect at least 50 cancers, with 43% positive predictive value and 44% sensitivity for all cancer types.

According to Grail, late diagnosis of cancers can lead to a 79% mortality rate at five years, compared with just 11% when they are diagnosed early.

Several companies have been developing tests for early cancer detection. These include Thrive Earlier Detection, which raised a $257 million Series B funding round that it will use to fund its registration-directed clinical study. The challenge in earlier detection is overcoming false positives, with even rates as low as 1% making a potentially big difference because, in larger populations, it can mean many patients still having to undergo tissue biopsy.

SHARE THIS POST
Posted in

About the author

Related Posts

Get Updates To Your Inbox

Startup Of The Week – Sequester (SQSTR)

SQSTR works with individuals and businesses to offset carbon through tree planting and renewable energy. Achieving net-zero is vital for our planet and SQSTR provides a platform to allow people and businesses to easily achieve this.